Background Recurrent ventricular tachycardia among survivors of myocardial infarction with
an implantable cardioverter–defibrillator (ICD) is frequent despite antiarrhythmic drug …

Clinically manifest cardiac involvement occurs in perhaps 5% of patients with sarcoidosis.
The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, …

Background There are no published clinical consensus guidelines or systematic evaluation
supporting the use of corticosteroids for the treatment of cardiac sarcoidosis. The purpose of …

Risk Factors and Complications of Pacemaker and ICD Infection. Background: Device‐related
infection is a major limitation of device therapy for cardiac arrhythmia. Methods: The …

Cardiac Sarcoidosis Presenting as Atrioventricular Block Introduction Atrioventricular block (AVB)
can be caused by several conditions, including cardiac sarcoidosis (CS). The …

Aims Guidelines recommend warfarin continuation rather than heparin bridging for
pacemaker and defibrillator surgery, after the BRUISE CONTROL trial demonstrated an 80% …

Introduction: Atrial fibrillation (AF) is the most frequent arrhythmia seen in clinical practice.
Until recently, antiarrhythmic medications have been the only commonly employed treatment …

Objectives : This study systematically reviewed the prevalence of pulmonary vein (PV)
reconnection in subjects with and without AF recurrence and assessed the relationship between …

EPIDEMIOLOGY Sarcoidosis has been reported to have a particular predilection for adults
under the age of 40 years. w1 The incidence of sarcoidosis varies greatly by ethnicity and …

Approximately 5% of patients with sarcoidosis will have clinically manifest cardiac involvement
presenting with one or more of ventricular arrhythmias, conduction abnormalities, and …